When there are bargains on stocks with long-term appeal, astute investors make sure to get a few shares while the getting is good. In truth, Moderna (NASDAQ: MRNA) is a bit of a contrarian purchase at the moment as nobody expects it to one-up its 2022 top line of nearly $19 billion now that sales of its coronavirus vaccine are expected to fall to as low as $5 billion in 2023.
CRISPR Therapeutics (NASDAQ: CRSP) has a couple of things in common with a company that's made the headlines over the past few years: coronavirus vaccine maker Moderna (NASDAQ: MRNA). Today, CRISPR's market value sits at about $3.4 billion. Since, Moderna has grown to become a $58 billion company, with a blockbuster product and three more potential ones on the horizon.
Moderna (NASDAQ: MRNA) helped some investors make a fortune over the past few years. The stock has climbed more than 400% since March 2020 -- that's when the company's coronavirus vaccine program gained traction. Recently, though, investors have worried about Moderna's post-pandemic revenue, and that's weighed on share performance.